195 related articles for article (PubMed ID: 19010183)
1. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation.
Moro JA; Almenar L; Martínez-Dolz L; Sánchez-Lázaro I; Agüero J; Salvador A
Transplant Proc; 2008 Nov; 40(9):3034-6. PubMed ID: 19010183
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis.
Baur B; Oroszlan M; Hess O; Carrel T; Mohacsi P
Transplant Proc; 2011 Jun; 43(5):1853-61. PubMed ID: 21693289
[TBL] [Abstract][Full Text] [Related]
4. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
5. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study.
Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Rueda J; Arnau MA; Agüero J; Sánchez-Lázaro I; Ortiz V; Salvador A
Transplant Proc; 2007 Sep; 39(7):2365-7. PubMed ID: 17889191
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
Fernandez-Valls M; Gonzalez-Vilchez F; de Prada JA; Ruano J; Ruisanchez C; Martin-Duran R
Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
[TBL] [Abstract][Full Text] [Related]
9. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors: do they help preserve renal function?
Moro J; Almenar L; Martínez-Dolz L; Agüero J; Rueda J; Arnau MA; Izquierdo M; Cano O; Sánchez-Lázaro I; Salvador A
Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
[TBL] [Abstract][Full Text] [Related]
13. Indications and management of everolimus after liver transplantation.
Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation.
Gonzalez-Vilchez F; Vazquez de Prada JA; Almenar L; Arizon Del Prado JM; Mirabet S; Diaz-Molina B; Delgado JF; Gomez-Bueno M; Paniagua MJ; Perez-Villa F; Roig E; Martínez-Dolz L; Brossa V; Lambert JL; Segovia J; Crespo-Leiro MG; Ruiz-Cano MJ
J Heart Lung Transplant; 2012 Mar; 31(3):288-95. PubMed ID: 22133787
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
[TBL] [Abstract][Full Text] [Related]
16. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
Roque E J; Ríos M G; Vignolo A P; Pinochet V C; Schultz M; Humeres A R; Delucchi A; Rius A M; Hepp K J
Rev Med Chil; 2008 May; 136(5):631-6. PubMed ID: 18769812
[TBL] [Abstract][Full Text] [Related]
17. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
18. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry.
Ruiz JC; Sánchez A; Rengel M; Beneyto I; Plaza JJ; Zárraga S; Errasti P; Andrés A; Morales JM; Torregrosa JV; Alarcón A; Morey A; Romero R; Fernández A; Díaz JM; Cantarell C;
Transplant Proc; 2007 Sep; 39(7):2157-9. PubMed ID: 17889123
[TBL] [Abstract][Full Text] [Related]
19. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
20. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
